NCT01853553
Mineralocorticoid Antagonism and Endothelial Dysfunction in Autosomal Dominant Polycystic Kidney Disease (ADPKD)
See it on ClinicalTrials.gov ↗61 people
54.1%
45.9%
33 womenmiddle line = equal numbers28 men
- Phase
- PHASE3
- Paid for by
- University of Colorado, Denver
- Finished
- 2017-01
- Health conditions
- ADPKD
- Who could join
- Anyone
- Ages
- 20 Years – 55 Years
- Average age
- mean 34 years
- Age 65+
- Not reported
- Weight (BMI)
- Not reported
- Pregnancy recorded
- Not reported
- Menopause recorded
- Not reported
- Results shown by sex
- Not split by sex
- Race
- Not reported
Women left out
- Age limit under 65
Older women were turned away, even though they often take this medicine.
“Maximum age: 55 Years.”
- No pregnant women
Women who were pregnant could not join.
“Pregnancy”
- Weight limit (BMI)
Women with a higher (or lower) body weight were turned away.
“BMI \< 40 kg/m2 (FMD measurements can be inaccurate in severely obese patients)”
- No kidney or liver problems
Women with kidney or liver problems were turned away.
“History of liver disease”
- No heart disease
Women with heart disease, heart rhythm problems or a past heart attack were turned away.
“History of heart failure (EF \< 35%)”
- No smokers
Women who smoke or use nicotine were turned away.
“Current smokers or history of smoking in the past 12 months”
Study titles and rules are shown in their original English.